SUN Pharmaceutical Industries Limited — Imatinib Exporter Profile
Indian Pharmaceutical Exporter · #3 for Imatinib · $2.9M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #3 Indian exporter of Imatinib with $2.9M in export value and 72 verified shipments. SUN Pharmaceutical Industries Limited holds a 9.9% market share in Imatinib exports across 7 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Imatinib Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Imatinib?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $864.1K | 42 | 45.3% |
| AUSTRALIA | $378.1K | 8 | 19.8% |
| PHILIPPINES | $238.4K | 6 | 12.5% |
| BELGIUM | $220.2K | 9 | 11.5% |
| BRAZIL | $107.2K | 7 | 5.6% |
| MEXICO | $100.0K | 2 | 5.2% |
| ROMANIA | $38 | 2 | 0.0% |
SUN Pharmaceutical Industries Limited exports Imatinib to 7 countries. The largest destination is UNITED STATES accounting for 45.3% of SUN Pharmaceutical Industries Limited's Imatinib shipments, followed by AUSTRALIA (19.8%) and PHILIPPINES (12.5%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Imatinib from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES,INC. | UNITED STATES | $396.0K | 12 |
| SUN PHARMACEUTICAL INDUSTRIES INC | UNITED STATES | $343.4K | 14 |
| SUN PHARMA ANZ PTY LTD. | AUSTRALIA | $278.1K | 6 |
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $220.2K | 9 |
| SUN PHARMA PHILIPPINES INC. | PHILIPPINES | $171.1K | 4 |
| SUN PHARMA ANZ PTY LTD., | AUSTRALIA | $100.0K | 2 |
| SUN PHARMA PHILIPPINES INC | PHILIPPINES | $67.3K | 2 |
| SUN FARMACEUTICA DO BRASIL LTDA. | BRAZIL | $50.0K | 1 |
| SUN PHARMACEUTICAL INDUSTRIESINC. | UNITED STATES | $50.0K | 1 |
| GRADINTER S.C | MEXICO | $50.0K | 1 |
SUN Pharmaceutical Industries Limited supplies Imatinib to 18 buyers globally. The largest buyer is SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES), followed by SUN PHARMACEUTICAL INDUSTRIES INC (UNITED STATES) and SUN PHARMA ANZ PTY LTD. (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Imatinib Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $18.5M worth of Imatinib through 1,726 shipments from 224 suppliers to 119 countries, serving 456 buyers globally. SUN Pharmaceutical Industries Limited contributes $2.9M to this total, accounting for 9.9% of India's Imatinib exports. SUN Pharmaceutical Industries Limited ships Imatinib to 7 countries through 18 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Imatinib Exports?
SUN Pharmaceutical Industries Limited's average Imatinib shipment value is $40.3K per consignment, based on 72 shipments totaling $2.9M. The largest destination is UNITED STATES (45.3% of SUN Pharmaceutical Industries Limited's Imatinib exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Imatinib Exporters?
SUN Pharmaceutical Industries Limited ranks #3 among 224 Indian Imatinib exporters with a 9.9% market share. The top 3 exporters are CIPLA LIMITED ($5.2M), EUGIA PHARMA SPECIALITIES LIMITED ($4.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($2.9M). SUN Pharmaceutical Industries Limited processed 72 shipments to 7 destination countries.
What Imatinib Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| IMATINIB Mesylate Tablets 400mg PACK : 30s Bottle Batch No. As Per DOCUMENT | $200.0K | 4 |
| IMATINIB MESYLATE TABLETS 400MG (IMATINI | $100.0K | 2 |
| IMATINIB Mesylate Tablets 400mg PACK : 3 | $97.6K | 2 |
| IMATINIB MESYLATE TABLETS 100 MG PACK : | $70.8K | 4 |
| IMATINIB MESYLATE TABLETS 400MG | $50.0K | 1 |
| IMALEK TAB 100MG TABLETS (IMATINIB MESYL | $50.0K | 1 |
| IMATINIB Mesylate Tablets 400mg PACK 30s Bottle Batch HAD3314A MFD 16 09 2022 EXP 31 08 2024 | $50.0K | 1 |
| IMATINIB MESYLATE TABLETS 100MG (IMATINI | $50.0K | 1 |
| IMALEK TAB 100MG IMATINIB MESYLATE TABL | $50.0K | 1 |
| IMATINIB Mesylate Tablets 400mg PACK : 30s Bottle BATCH DETAILS AS PER DOCUMENT | $50.0K | 1 |
SUN Pharmaceutical Industries Limited exports 56 distinct Imatinib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is IMATINIB Mesylate Tablets 400mg PACK : 30s Bottle Batch No. with 4 shipments worth $200.0K.
Regulatory Requirements: Exporting Imatinib to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Imatinib to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Imatinib Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED | $5.2M | 103 | 8 | $50.0K |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $4.1M | 82 | 2 | $50.0K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $2.9M | 72 | 7 | $40.3K |
| 4 | JODAS EXPOIM PRIVATE LIMITED | $1.9M | 38 | 3 | $50.0K |
| 5 | NATCO PHARMA LIMITED | $1.3M | 33 | 9 | $39.7K |
SUN Pharmaceutical Industries Limited ranks #3 among 224 Indian Imatinib exporters. Average shipment value of $40.3K compared to the market average of $82.5K. The closest competitors by value are CIPLA LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Which Indian Ports Ship Imatinib Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 314 | 18.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 301 | 17.4% |
| DELHI AIR CARGO ACC (INDEL4) | 235 | 13.6% |
| DELHI AIR | 142 | 8.2% |
| Bombay Air | 123 | 7.1% |
| HYDERABAD AIR | 69 | 4.0% |
| HYDERABAD ACC (INHYD4) | 61 | 3.5% |
| AHEMDABAD AIR | 35 | 2.0% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Imatinib Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Imatinib, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Imatinib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Imatinib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 76 individual customs records matching SUN Pharmaceutical Industries Limited exporting Imatinib, covering 56 formulations to 7 countries via 18 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 119+ countries, 456+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Imatinib Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Imatinib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Imatinib Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Imatinib. For current shipment-level data, contact TransData Nexus.